Sponsor Pipeline

Daiichi Sankyo Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
59
Active Trials
31
Recruiting
21
Phase 3
10
Disease Areas
28
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-13 NCT05875168
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Trial sites expanded: 33 -> 36 locations
2026-08-11 NCT07681882
First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors
Recruitment opened
2026-08-08 NCT07474649
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without…
Trial sites expanded: 0 -> 12 locations
2026-08-06 NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects…
Phase changed: Phase 2 -> Phase 1/2
2026-08-06 NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects…
Primary endpoint(s) modified
2026-08-06 NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects…
Enrollment increased: 520 -> 680 participants
2026-08-06 NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects…
Trial arms changed: 13 -> 14
2026-08-06 NCT06203210
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With…
Primary endpoint(s) modified
2026-08-06 NCT06203210
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With…
Trial sites reduced: 232 -> 229 locations
2026-08-06 NCT06203210
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With…
date change Primary completion pushed: 2027-04-30 -> 2028-01-30
2026-08-06 NCT06203210
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With…
date change Completion pushed: 2029-02-22 -> 2029-12-01
2026-08-05 NCT06644781
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic…
Trial sites expanded: 88 -> 132 locations
2026-08-01 NCT07206472
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in…
Enrollment reopened
2026-08-01 NCT07206472
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in…
Enrollment reduced: 2560 -> 2120 participants
2026-08-01 NCT07206472
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in…
Trial sites expanded: 1 -> 23 locations
2026-08-01 NCT07206472
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in…
date change Primary completion pushed: 2028-09-01 -> 2028-11-22
2026-08-01 NCT07206472
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in…
date change Completion moved earlier: 2029-03-01 -> 2028-12-31
2026-07-29 NCT06161025
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade…
Trial sites expanded: 152 -> 164 locations
2026-07-29 NCT03030066
Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
Trial completed
2026-07-29 NCT03030066
Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
date change Completion moved earlier: 2026-08-31 -> 2026-07-16
Showing 20 of 28 changes detected in the last 30 days.
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-07-31 NCT07739966 A Study of DS-3939a in Participants With Solid Tumors Phase 1/2 Not Yet Recruiting
Active Trials by Phase
Phase 3
19
Phase 2/3
2
Phase 2
6
Phase 1/2
9
Phase 1
16
Not specified
7
Active Trials — top 25 of 59
NCT IDTitleConditionStatus
Phase 3
NCT06174987 A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) Advanced Cancer Recruiting
NCT05950945 Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone… Breast Cancer Recruiting
NCT06819007 Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for… Ovarian Cancer Recruiting
NCT06899126 Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in… Non-small Cell Lung Cancer Recruiting
NCT07022483 Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing… Endometrial Cancer Recruiting
NCT06644781 A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic… Esophageal Squamous Cell Carcinoma Recruiting
NCT06203210 A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With… Small Cell Lung Cancer Recruiting
NCT06731478 Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic… Gastric Cancer Recruiting
NCT05338970 HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in… Nonsquamous Non-small Cell Lung Cancer Active, Not Recruiting
NCT03734029 Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer… Breast Cancer Active, Not Recruiting
NCT03529110 DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive… Breast Cancer Active, Not Recruiting
NCT04622319 A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in… HER2-Positive Primary Breast Cancer Active, Not Recruiting
NCT04704934 Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or… Gastric Cancer, Adenocarcinoma Active, Not Recruiting
NCT05215340 Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment… Metastatic Non Small Cell Lung Cancer Active, Not Recruiting
NCT05555732 Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy… Metastatic Non Small Cell Lung Cancer Active, Not Recruiting
NCT06578247 Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD… Leukemia Active, Not Recruiting
NCT07683754 T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line… Advanced Breast Cancer Not Yet Recruiting
NCT04656652 Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small… Non-small Cell Lung Cancer Active, Not Recruiting
NCT07474649 A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without… Coronary Atherosclerosis Not Yet Recruiting
Phase 2/3
NCT07129993 Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus… Urothelial Cancer Recruiting
NCT06161025 A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade… Solid Cancer Recruiting
Phase 2
NCT06824168 Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid… Acute Myeloid Leukemia Recruiting
NCT06172478 A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Advanced Solid Tumor Recruiting
NCT05280470 Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung… Extensive-stage Small-cell Lung Cancer Active, Not Recruiting
NCT06660654 A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors… Advanced Solid Tumor Active, Not Recruiting
See all 59 active Daiichi Sankyo trials with filters →
Disease Areas
Get alerts when Daiichi Sankyo's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free